Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Tezosentan

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 2 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

2Total
Phase 3 (2)

Trial Status

Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT00524433Phase 3Completed

Tezosentan in the Treatment of Acute Heart Failure

NCT00525707Phase 3Completed

Tezosentan in Acute Heart Failure

Showing all 2 trials

Research Network

Common Treatments

  • Tezosentan2

Active Sponsors

  • Idorsia Pharmaceuticals Ltd.2

Related Conditions

  • Acute Heart Failure2
  • New Onset Of Heart Failure2

Activity Timeline